Company Overview and News

3
Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release

11h zacks
Merck & Co., Inc. (MRK - Free Report) stock has risen 4.2% since the company announced second-quarter earnings on Jul 27.
MRK AZN AMGN AZN INCY

6
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

2018-08-13 zacks
Chicago, IL –August 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk (NVO - Free Report) , J&J (JNJ - Free Report) , Allergan (AGN - Free Report) , Editas Medicine, Inc. (EDIT - Free Report) , AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Bristol-Myers (BMY - Free Report) .
MRK HD AZN EPM EDIT AGN AZN EPM-A BGSF

0
Zacks Investment Ideas feature highlights: Merck and Amgen

2018-08-06 zacks
Chicago, IL – August 6, 2018 – Today, Zacks Investment Ideas feature highlights Features: Merck (MRK - Free Report) ) and Amgen (AMGN - Free Report) .
MRK AMGN CY BGSF FUN

7
Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval

2018-08-03 zacks
Pfizer’s (PFE - Free Report) strong second-quarter results stole the show this week. Other than that, the European Commission approved Pfizer’s first oncology biosimilar and a second indication for its JAK inhibitor, Xeljanz and Bristol-Myers’ (BMY - Free Report) Opdivo for a melanoma indication. Meanwhile, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave its opinion recommending/not recommending approval of several drugs in Europe.
MRK AZN AZN NVS PFE SNY

8
Merck's Keytruda Improves Survival in Head/Neck Cancer Study

2018-07-25 zacks
Merck & Co., Inc. (MRK - Free Report) announced that its PD-L1 inhibitor, Keytruda, met primary endpoint of overall survival (OS) in a pivotal phase III study. The phase III KEYNOTE-048 study evaluated Keytruda as a monotherapy for the first-line treatment of advanced head and neck squamous cell carcinoma (HNSCC) in patients whose tumors expressed PD-L1 (combined proportion score (CPS) ≥20).
MRK LMT AMGN BP DTJ GSK BP.A BP.B BP DTW DTV GSK BPAQF DTY PFE

5
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer

2018-07-12 zacks
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has granted priority review to a supplemental new drug application (sBLA) for its PD-L1 inhibitor, Keytruda.
MRK AMGN GSK PFE GSK

23
Using Ratios To Identify Stocks Set To Outperform Their Peers: Pharmaceutical Rankings Update

2018-07-09 seekingalpha
Year to Date performance is presented along with how this is related to each stock's final score.
MRK GILD JNJ ABBV PFE ABBV

51
Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review

2018-07-06 zacks
The Dow traversed a holiday-shortened week during which trading volumes remained low. A rally in tech shares helped the index rebound on Monday after initial hiccups on trade tensions. However, a tech selloff reversed early gains, leading to losses for the index on Tuesday. Markets were closed on Wednesday for the Fourth of July holiday. The index advanced on Thursday, boosted by tech stocks which posted their best performance in more than a month.
FB CAT NFLX MRC GS GLSSP AMZN BOE AAPL INTC IBM MRK JBK GSC TFG GSJ TXT BA GJS

0
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer

2018-07-03 zacks
Merck and Co., Inc. (MRK - Free Report) gained priority review for yet another supplemental biologics license application (sBLA) for its PD-1 inhibitor, Keytruda. With the latest application, Merck is looking to get Keytruda approved in combination with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC), which is a difficult-to-treat lung cancer patient population.
MRK AMGN INCY

107
Merck (MRK) Stock Up So Far This Year on Keytruda Strength

2018-06-22 zacks
Merck & Co., Inc. (MRK - Free Report) shares have performed well this year so far in contrast to its industry’s performance. Merck belongs to the Zacks Large Cap Pharmaceuticals industry, which is a 14-stock group comprising some of the largest drugmakers of the world.
MRK AZN AMGN AZN

181
Bristol-Myers Top NASH Contenders

2018-06-12 seekingalpha
There were whispers in the marketplace that Bristol Myers-Squibb (NYSE:BMY) was still looking to beef up their pipeline in NASH but Dealreporter broke the news that the BMY’s business development chief Paul Biondi is “actively looking for acquisition or license opportunities in fibrotic diseases.” After this speculation broke out, it buoyed the valuations of the some of the NASH players. Keep in mind this was on the heels of Madrigal’s (NASDAQ:MDGL) favorable clinical trial announcement.
MRK MDGL GILD GALTW GALTU GNFTF ICPT VKTX GALT VKTXW MRK CTMX NVS BMY CBAY

179
Bristol Meyers Top NASH Contenders

2018-06-12 seekingalpha
There were whispers in the marketplace that Bristol Myers-Squibb (NYSE:BMY) was still looking to beef up their pipeline in NASH but Dealreporter broke the news that the BMY’s business development chief Paul Biondi is “actively looking for acquisition or license opportunities in fibrotic diseases.” After this speculation broke out, it buoyed the valuations of the some of the NASH players. Keep in mind this was on the heels of Madrigal’s (NASDAQ:MDGL) favorable clinical trial announcement.
MRK MDGL GILD GALTW GALTU GNFTF ICPT VKTX GALT VKTXW MRK CTMX NVS BMY CBAY

218
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

2018-06-11 zacks
Chicago, IL – June 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol Myers (BMY - Free Report) , Merck (MRK - Free Report) , Roche (RHHBY - Free Report) , Lilly (LLY - Free Report) and AbbVie (ABBV - Free Report) .
RYAM MRK NKTR KBH HSC WLK ALSN LB MCHP TRTN BGSF MU SCVL CCK ABBV OXY ABBV

351
This One Study Could Radically Change The Cancer Immunotherapy Market

2018-06-07 seekingalpha
The cause is speculated to be that antibiotics clear the gut of bacteria, which decreases the amount of circulating immune cells, which in turn lessens the effect of immunotherapy.
SGEN MRK TSRO AMGN BMYMP ADXS BLUE CELG BLUE SNDX BMY

113
3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

2018-06-04 zacks
In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. Moreover, quite a few negative pipeline and regulatory updates announced this year so far have probably had an unfavorable impact on the industry.
MRK AZN DB CELGZ AZN IPXL CELG NVS GSK GSK SNY

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...